Astellas’s Long-Term Safety Data Could Boost Fezolinetant’s Approval Chances

 
• By Joseph Haas
  
hot flash VMS
Astellas hopes to bring a nonhormonal therapy for hot flashes to market • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D